Teladoc Health reported its first-quarter 2025 financial results, posting revenue of $629.4 million, a 2.6% decline year-over-year, which exceeded analyst estimates of $619.3 million. The company recorded a net loss of $93.0 million, or $0.53 per share, which was wider than the estimated loss of $0.34 per share. This loss included a pre-tax goodwill impairment charge of $59.1 million. Adjusted EBITDA stood at $58.1 million, down 8% year-over-year but above the $53.3 million estimate. Total visits fell 3.5% year-over-year to 4.44 million, missing the estimated 4.96 million visits. Teladoc provided second-quarter 2025 revenue guidance in the range of $614 million to $633 million. In a strategic move to expand its virtual mental health services, Teladoc acquired UpLift, a virtual mental health provider, for $30 million in an all-cash deal. This acquisition aims to bolster Teladoc's mental health offerings, particularly to support its struggling BetterHelp unit. Meanwhile, Tandem Diabetes Care reported first-quarter 2025 revenue of $234.42 million, beating estimates of $220.20 million, but its adjusted EPS of negative $0.67 missed the $0.61 estimate. DexCom also released its first-quarter 2025 results, with revenue of $1.036 billion, up 12% year-over-year and beating estimates of $1.02 billion. However, its adjusted EPS of $0.32 slightly missed the $0.33 estimate. DexCom reaffirmed its 2025 revenue guidance of $4.6 billion, representing 14% growth, while lowering its full-year non-GAAP gross profit margin guidance to approximately 62%.